CN1682706A - Stable oil-in-water emulsion of propyl gallate for vein and its preparing method - Google Patents
Stable oil-in-water emulsion of propyl gallate for vein and its preparing method Download PDFInfo
- Publication number
- CN1682706A CN1682706A CN 200510038073 CN200510038073A CN1682706A CN 1682706 A CN1682706 A CN 1682706A CN 200510038073 CN200510038073 CN 200510038073 CN 200510038073 A CN200510038073 A CN 200510038073A CN 1682706 A CN1682706 A CN 1682706A
- Authority
- CN
- China
- Prior art keywords
- oil
- compositions according
- propyl ester
- emulsion
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to propyl gallate composition in stable oil-in-water emulsion for vein, and the method of mixing propyl gallate into oil to form stable oil-in-water emulsion. The composition includes propyl gallate, oil, surfactant, antioxidant, cosolvent and water. In one optimal scheme, the oil is soybean oil, the surfactant is yolk lecithin, the antioxidant is vitamin E and the cosolvent is benzyl alcohol. The cosolvent solution of propyl gallate is dissolved in soybean oil to form the oil solution of propyl gallate, and the oil solution is dispersed in water with the surfactant to form the stable oil-in-water emulstion for vein.
Description
Technical field
The present invention relates to the Gallate propyl ester, it is specifically related to for the propyl gallate for vein composition and method of making the same.
Background technology
The Gallate propyl ester is the derivant of the active component-epicatechol gallate in the Chinese medicine Radix Paeoniae Rubra, be on the structure of epicatechol gallate, modify and obtain have a more medicine of Johnson ﹠ Johnson's thing effect.Its chemistry is by name: 3,4, and the 5-Propylgallate, molecular formula is C
10H
12O
5, structure is as follows:
Prove through pharmaceutical research, the Gallate propyl ester has multiple biological activity, as antiplatelet aggregation, enhancing fibrinolytic, promote thromboembolism, reduce whole blood contrast viscosity and plasma viscosity, accelerate erythrocyte electrophoresis speed, lax vascular smooth muscle, expansion artery, the effects such as inflammatory exudation that improve anti-hypobaric hypoxia ability, removing free radical, inhibition blood capillary.The clinical treatment that is used for ischemic cerebrovascular (as acute cerebral infarction, chronic brain thrombosis, lacunar infarction, cerebral blood supply insufficiency), coma sequela, cerebral trauma, cerebral concussion etc. also is used for coronary heart disease, angina pectoris, hypertension, heart failure; Pulmonary heart disease and some peripheral angiopathy (as thrombophlebitis).
The listing dosage form of Gallate propyl ester comprises injection Gallate propyl ester, Gallate propyl ester injection, Gallate propyl ester sodium chloride injection at present.Defectives such as these dosage forms exist poor stability, and are bigger to people's blood vessel irritation, need frequent drug administration in the therapeutic process, and biocompatibility difference and bioavailability are low.
The Emulsion of intravenously administrable is the targeted drug carrier, belongs to the novel form of targeting drug delivery system.The characteristics of this dosage form are: particle disperses, be the lipoid microsphere structure, enter to change behind the human body and distributed in the body of medicine carrying thing, main liver the people, spleen, distributed density is higher in the histoorgans such as lung and bone marrow, the lymphsystem directivity is arranged, thereby improve the therapeutic index of medicine, reduce the toxicity of the therapeutic dose and the reduction medicine of medicine, and can regulate body's immunological function.
Summary of the invention
In conjunction with many weak points of the existing preparation of Gallate propyl ester, the oil in water emulsion that we have developed the Gallate propyl ester is the propyl gallate for vein lipomul.The present invention relates to the stable oil in water emulsion compositions of Gallate propyl ester used for vein, also relate to the Gallate propyl ester molten in oil and make the method for stable oil in water emulsion.
Said composition comprises the Gallate propyl ester, oil, surfactant and co-emulsifier, antioxidant, cosolvent, water; In described oil, described Gallate propyl ester oil solution forms stable decentralized photo to the dose that wherein said Gallate propyl ester is used with vein in water by solubilization.
Oil is that a physiology big class wide region, that have different chemical character can be accepted material, is selected from or comes mineral oil, vegetable oil, animal oil, quintessence oil or artificial oil freely.In the animal oil classification usually from sebum, Adeps Sus domestica and stearic fat, fish oil, oleic acid, sperm oil; Vegetable oil such as soybean oil, Semen Maydis oil, Oleum Arachidis hypogaeae semen, Oleum sesami, olive oil, Semen Lini oil, Oleum Gossypii semen, safranine caul-fat, Oleum Verniciae fordii, Oleum Ricini, Oleum Cocois or Petiolus Trachycarpi oil.Oil also can be in the above-mentioned oil more than one miscella.Aqueous fatty oil such as single, double, triglyceride or its mixture are preferred oil.The triglyceride of medium chain also are useful oil.
Oil more preferably is rich in the oil such as the soybean oil of triglyceride.
Used surfactant can be any surfactant, any suitable surfactant (no matter natural or synthetic, traditional or novel surfactant, comprise anion, cation, nonionic and zwitterionic surfactant) all can use separately or the compound use of more than one surfactants, also comprise and can add one or more any suitable co-emulsifier.
Surfactant or co-emulsifier, as available egg yolk lecithin or soybean phospholipid (as lecithin), Pluronics (as Pluronics F68), cholesterol, the cholesterol of ethoxylation, diacetyl glycerol and dialkyl ether glycerol etc., Emulsion of the present invention also can contain alkyl phosphorylcholine or the alkyl glycerol Phosphorylcholine surfactant that Kaufman and Richard describe in the U.S. Patent No. 791.420 of application on November 13rd, 1991, object lesson has: 1,2-dioctyl glycerol-3-Phosphorylcholine, 1, the two myristyl glycerol of 2--3-Phosphorylcholine, 1,2-double hexadecyl glycerol-3-Phosphorylcholine, two octadecyl glycerol-3-Phosphorylcholine, 1-cetyl-2-myristyl glycerol-3-Phosphorylcholine, 1-octadecyl-2-myristyl glycerol-3-Phosphorylcholine, 1-myristyl-2-octadecyl glycerol-3-Phosphorylcholine, 1-cetyl-2-octadecyl glycerol-3-Phosphorylcholine, 1, the two octadecyl glycerol of 2--3-Phosphorylcholine, 1-octadecyl-2-cetyl glycerol-3-Phosphorylcholine, 1-myristyl-2-cetyl glycerol-3-Phosphorylcholine, 2, the two myristyls of 2--1-Phosphorylcholine ethane and 1-cetyl-myristyl glycerol-3-Phosphorylcholine.Also can be used on the dialkyl group glyceryl phosphoryl choline that Kaufman and Richard describe in the U.S. Patent No. 08/228.224 of application on April 15th, 1994.Anion surfactant comprises alkyl or aryl sulfuric acid ester, sulfonic acid fat, carboxylic esters or phosphoric acid fat.Cationic surfactant comprise as single, double, three and tetraalkyl or aryl ammonium salt.Ionic surfactant pack is drawn together the alkyl or aryl chemical compound, and its hydrophilic segment is by polyoxyethylene chain, glycan molecule, and polyol derivative or other hydrophilic group are formed.Zwitterionic surfactant can be above-mentioned anion or cationic surfactant in conjunction with product, its hydrophilic segment comprises any other kind of polymer, as polyoxy isobutene. or poly(propylene oxide).
Co-emulsifier can also be carbon number 6～22, preferred 10～20 fatty acid and physiologically acceptable salt.The fatty acid of this carbon number 6～22 is so long as pharmaceutically allow, and any fatty acid can.Fatty acid can be straight chain or side chain, the preferably stearic acid of the straight chain of carbon number 10～20, oleic acid, linoleic acid, Palmic acid, linolein acid, tetradecanoic acid etc., can enumerate acceptable salt on its physiology as these hydrochlorates, alkali metal salt such as sodium, potassium for example, alkali salts such as calcium salt etc.
Surfactant is preferably phospholipid such as Ovum Gallus domesticus Flavus lecithin.
Co-emulsifier is preferably oleic acid.
Used antioxidant comprises the mixture of sulphite, vitamin C derivatives, thio-compounds, amino acids, organic acid, phenols, amine, oil-soluble antioxidant, chelating agen and wherein any two kinds or above antioxidant.Be preferably oil-soluble antioxidant, comprise ascorbyl palmitate, butylated hydroxyarisol, di-tert-butyl hydroxy-methylbenzene, the mixture of vitamin E and wherein any two kinds or above antioxidant.
Antioxidant is preferably oil-soluble antioxidant vitamin E.
Used cosolvent comprises ethanol, propylene glycol, glycerol, 1,3-butanediol, tertriary amylo alcohol, Polyethylene Glycol, benzyl alcohol, N, dinethylformamide, N,N-dimethylacetamide, N-(beta-hydroxyethyl) lactamide, dimethyl sulfoxide, triacetyl glycerine, ethyl lactate, ethyl oleate, isopropyl myristate, benzyl benzoate or vegetable oil.
Cosolvent is preferably benzyl alcohol.
Typically, be that the consumption of Gallate propyl ester is 0.01% to 5% in Emulsion weight, the consumption of oil is 1% to 40%, and the consumption of surfactant is 0.01% to 10%, and the consumption of co-emulsifier is 0% to 10%, the consumption of antioxidant is 0.01% to 1%, and the cosolvent consumption is 0.01% to 1%.
If desired, also can add one or more additives in the compositions.As add the permeability that glycerol is regulated compositions.Usually add q.s glycerol (being generally 0～5%) and transfer every liter of permeability to 280～320 milli osmol(e)s.Also can add more or less triglyceride to make the solution of high infiltration or hyposmosis according to required final use.In addition according to required final use, also can add the mixture that typical additives in the compositions has glucose, mannitol, xylitol, sorbitol or Ru Suannalingeshi (Ringer ' s) liquid and wherein any two kinds or above regulator.
Also can add sterol, C
14-C
22Pure and mild phosphatidic acid is as coemulsifier.Usually select sterol such as cholesterol or long-chain (C for use
14-C
22) alcohol makes coemulsifier.If use, be that the general consumption of this class material is 0～1% in Emulsion weight.
The Gallate propyl ester can multiple concentration be sneaked into, and typical concentration is 1.2mg Gallate propyl ester/ml Emulsion.
The present invention also relates to the preparation method of the stabilized oil-in-water emulsion of Gallate propyl ester on the other hand, the oil solution that is about to the Gallate propyl ester is distributed to the method for the oil in water emulsion that formation is stable in the water: the Gallate propyl ester is dissolved in the cosolvent, adds to that mixing obtains oil phase in the oil that adds antioxidant; Surfactant can be distributed in the oil phase or aqueous phase; Wherein the water alternative comprises glycerol to regulate required permeability, under the situation of high-speed stirred water, evenly pours oil phase into water to form primary emulsion, and primary emulsion is transferred to the homogenizer homogenizing, and then after filtration, embedding and sterilization promptly get Emulsion.
Trial-produce successfully for the propyl gallate for vein oil in water emulsion, and compare with other preparation of kind, its stable, efficient, low toxic and side effects, excellent biological compatibility show its good preparation that meets very much the cardiovascular and cerebrovascular disease needs of patients really.
The Gallate propyl ester Emulsion that we developed and former dosage form relatively, it has certain slow-releasing, has reduced the toxic and side effects of medicine and to the zest of blood vessel; Medicine has also improved stability of drug because of being wrapped in the oil droplet.Therefore Gallate propyl ester Emulsion be a kind of stable, efficient, low toxic and side effects, preparation with excellent biological compatibility.
Its advantage is embodied in:
1, slow-releasing: the Gallate propyl ester that is wrapped in the Emulsion slowly continues to discharge from lipoid microsphere, has prolonged action time.
2, high efficiency: reduced administration number of times, brought into play higher curative effect.
3, reduced toxic and side effects and to the zest of blood vessel: the Gallate propyl ester is wrapped in the lipoid microsphere, and because of barrier action has significantly reduced blood vessel irritation and inflammatory reaction, said composition is good, the easy thing of degraded of biocompatibility;
4, improved stability of drug: the Gallate propyl ester is wrapped in has obviously improved stability in the lipoid microsphere.
The specific embodiment
Below will do further understanding to relevant purposes more of the present invention by infinite embodiment.
Embodiment 1
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the soybean oil (added vitamin E 0.6g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with 22.5g glycerol, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 2
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the soybean oil (added vitamin E 0.6g) of 100g and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with 22.5g glycerol and 12g Ovum Gallus domesticus Flavus lecithin, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 3
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the soybean oil (added vitamin E 0.6g and oleic acid 0.3g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, the water for injection (about 800ml) that above-mentioned oil phase is slowly injected, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 4
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the soybean oil (added vitamin E 0.6g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected water for injection (about 800ml), stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 5
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the Oleum Gossypii semen (added vitamin E 0.6g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with 22.5g glycerol, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 6
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the soybean oil (added vitamin E 0.6g) of 100g respectively with soybean lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with 22.5g glycerol, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 7
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the soybean oil (added vitamin E 0.6g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with 22.5g glycerol and 2.0g cholesterol, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 8
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the soybean oil of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase slowly injected be added with 22.5g glycerol and the ascorbic water for injection of 0.6g (about 800ml), stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 9
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the soybean oil (added di-tert-butyl hydroxy-methylbenzene 0.2g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with 22.5g glycerol, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 10
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 6g propylene glycol, dissolve in the soybean oil (added vitamin E 0.6g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with 22.5g glycerol, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 11
The preparation of Gallate propyl ester liplid emulsions
1.2g is dissolved in 4g N with the Gallate propyl ester, in the N-dimethyl acetylamide, dissolve in the soybean oil (added vitamin E 0.6g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with 22.5g glycerol, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 12
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 5g ethyl oleate, dissolve in the soybean oil (added vitamin E 0.6g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with 22.5g glycerol, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Embodiment 13
The preparation of Gallate propyl ester liplid emulsions
Gallate propyl ester 1.2g is dissolved in the 8g benzyl alcohol, dissolve in the soybean oil (added vitamin E 0.6g) of 100g respectively with Ovum Gallus domesticus Flavus lecithin 12g again and make oil phase through being heated to 80 ℃, under the high-speed stirred condition, above-mentioned oil phase is slowly injected the water for injection (about 800ml) that is added with the 50g glucose, stir 30min under the 7000rpm condition and make colostrum (being settled to 1000ml), change homogenizer over to through high pressure homogenize, then after filtration, embedding and sterilization (100 ℃ * 30min) promptly.
Claims (38)
1. the compositions of a stabilized oil-in-water emulsion that contains the Gallate propyl ester of using for vein, it comprises:
The Gallate propyl ester;
Oil;
Surfactant;
Antioxidant;
Cosolvent; With
Water;
In described oil, described Gallate propyl ester oil solution forms stable decentralized photo to the dose that wherein said Gallate propyl ester is used with vein in water by solubilization.
2. compositions according to claim 1, wherein said oil are meant the acceptable mineral oil of any physiology, vegetable oil, animal oil, quintessence oil or artificial oil.
3. compositions according to claim 2, wherein said oil are the vegetable oil that is rich in triglyceride.
4. compositions according to claim 3, the wherein said vegetable oil that is rich in triglyceride is soybean oil, Semen Maydis oil, Oleum Arachidis hypogaeae semen, Oleum sesami, olive oil, Semen Lini oil, Oleum Gossypii semen, safranine caul-fat, Oleum Verniciae fordii, Oleum Ricini, Oleum Cocois or Petiolus Trachycarpi oil.
5. compositions according to claim 4, the wherein said vegetable oil that is rich in triglyceride is a soybean oil.
6. compositions according to claim 1, wherein said surfactant is a phospholipid.
7. compositions according to claim 6, wherein said phospholipid is Ovum Gallus domesticus Flavus lecithin.
8. compositions according to claim 1 wherein also can contain co-emulsifier.
9. compositions according to claim 8, wherein said co-emulsifier are side chain or the straight chain fatty acid and the physiologically acceptable salt of carbon number 10～20.
10. compositions according to claim 9, the straight chain fatty acid of wherein said carbon number 10～20 are acceptable sodium, potash slaine on stearic acid, oleic acid, linoleic acid, Palmic acid, linolein acid or tetradecanoic acid and the physiology, the calcium salt alkali salt.
11. compositions according to claim 10, wherein said co-emulsifier are oleic acid.
12. compositions according to claim 1 wherein also can contain the permeability regulator.
13. compositions according to claim 12, wherein said permeability regulator can be selected from the mixture of glycerol, glucose, mannitol, sorbitol, xylitol, Ru Suannalingeshi (Ringer ' s) liquid and wherein any two kinds or above regulator.
14. compositions according to claim 13, wherein said permeability regulator is a glycerol.
15. compositions according to claim 1, wherein said antioxidant can be selected from the mixture of sulphite, vitamin C derivatives, thio-compounds, amino acids, organic acid, phenols, amine, oil-soluble antioxidant, chelating agen and wherein any two kinds or above antioxidant.
16. compositions according to claim 15, wherein said oil-soluble antioxidant can be selected from ascorbyl palmitate, butylated hydroxyarisol, di-tert-butyl hydroxy-methylbenzene, the mixture of vitamin E and wherein any two kinds or above antioxidant.
17. compositions according to claim 16, wherein said oil-soluble antioxidant is vitamin E.
18. compositions according to claim 1, wherein said cosolvent can be selected from ethanol, propylene glycol, glycerol, 1,3-butanediol, tertriary amylo alcohol, Polyethylene Glycol, benzyl alcohol, N, dinethylformamide, N,N-dimethylacetamide, N-(beta-hydroxyethyl) lactamide, dimethyl sulfoxide, triacetyl glycerine, ethyl lactate, ethyl oleate, isopropyl myristate, benzyl benzoate or vegetable oil.
19. compositions according to claim 18, wherein said cosolvent are benzyl alcohol.
20. compositions according to claim 1, it can also comprise and is selected from sterol, C
14-C
22The additive of pure and mild phosphatidic acid.
21. compositions according to claim 20, wherein said sterol are cholesterol.
22. compositions according to claim 1, wherein in Emulsion weight, the consumption of described Gallate propyl ester is 0.01%～5%.
23. compositions according to claim 1, wherein in Emulsion weight, the consumption of described oil is 1%～40%.
24. compositions according to claim 1, wherein in Emulsion weight, the consumption of described surfactant is 0.01%～10%.
25. compositions according to claim 1, wherein in Emulsion weight, the consumption of described co-emulsifier is 0%～10%.
26. compositions according to claim 14, wherein in Emulsion weight, the consumption of described glycerol is 0%～5%.
27. compositions according to claim 1, wherein in Emulsion weight, the consumption of described antioxidant is 0.01%～1%.
28. compositions according to claim 1, wherein in Emulsion weight, the consumption of described cosolvent is 0.01%～1%.
29. compositions according to claim 21, wherein in Emulsion weight, the consumption of described cholesterol is 0%～1%.
30. compositions according to claim 1, wherein said Gallate propyl ester is sneaked in the described Emulsion with the concentration of 1.2mg/ml Emulsion.
31. a vein is with the preparation method of the stabilized oil-in-water emulsion that contains the Gallate propyl ester: the Gallate propyl ester is dissolved in the cosolvent, adds to that mixing obtains oil phase in the oil that adds antioxidant; Surfactant can be distributed in the oil phase or aqueous phase; Wherein the water alternative comprises glycerol to regulate required permeability, under the situation of high-speed stirred water, evenly pours oil phase into water to form primary emulsion, and primary emulsion is transferred to the homogenizer homogenizing, and then after filtration, embedding and sterilization promptly get Emulsion.
32. method according to claim 31, wherein said cosolvent is ethanol, propylene glycol, glycerol, 1,3-butanediol, tertriary amylo alcohol, Polyethylene Glycol, benzyl alcohol, N, dinethylformamide, N,N-dimethylacetamide, N-(beta-hydroxyethyl) lactamide, dimethyl sulfoxide, triacetyl glycerine, ethyl lactate, ethyl oleate, isopropyl myristate, benzyl benzoate or vegetable oil.
33. method according to claim 32, wherein said cosolvent are benzyl alcohol.
34. compositions according to claim 31, wherein said oil are meant the acceptable mineral oil of any physiology, vegetable oil, animal oil, quintessence oil or artificial oil.
35. compositions according to claim 34, wherein said oil are the vegetable oil that is rich in triglyceride.
36. compositions according to claim 35, the wherein said vegetable oil that is rich in triglyceride is a soybean oil.
37. method according to claim 31, wherein said surfactant is a phospholipid.
38. according to the described method of claim 37, wherein said phospholipid is Ovum Gallus domesticus Flavus lecithin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100380730A CN100333722C (en) | 2005-03-11 | 2005-03-11 | Stable oil-in-water emulsion of propyl gallate for vein and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100380730A CN100333722C (en) | 2005-03-11 | 2005-03-11 | Stable oil-in-water emulsion of propyl gallate for vein and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682706A true CN1682706A (en) | 2005-10-19 |
| CN100333722C CN100333722C (en) | 2007-08-29 |
Family
ID=35262327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100380730A Expired - Fee Related CN100333722C (en) | 2005-03-11 | 2005-03-11 | Stable oil-in-water emulsion of propyl gallate for vein and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100333722C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912362A (en) * | 2010-09-01 | 2010-12-15 | 北京大学 | A kind of fat emulsion pre-emulsified concentrate for intravenous injection of teniposide and preparation method thereof |
| CN102106817B (en) * | 2009-12-29 | 2012-11-07 | 四川科伦药物研究有限公司 | Propyl gallate pre-emulsified concentrated solution and preparation thereof |
| CN109414054A (en) * | 2016-07-19 | 2019-03-01 | 巴斯夫欧洲公司 | Vitamin prepared product containing propyl gallate |
| CN111345290A (en) * | 2012-03-05 | 2020-06-30 | 阿彻丹尼尔斯米德兰德公司 | Microemulsions and their use as delivery systems |
| CN114010597A (en) * | 2021-11-25 | 2022-02-08 | 广州白云山汉方现代药业有限公司 | Propyl gallate fat emulsion injection with special grease proportion and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616330A (en) * | 1994-07-19 | 1997-04-01 | Hemagen/Pfc | Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same |
| CN1481787A (en) * | 2003-07-29 | 2004-03-17 | 吉林市卓怡康纳制药有限公司 | Propylgallate injection and its preparing process |
| CN1254245C (en) * | 2003-08-26 | 2006-05-03 | 曹永强 | Hydroxy camptothecin emulsion and its preparation method |
-
2005
- 2005-03-11 CN CNB2005100380730A patent/CN100333722C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106817B (en) * | 2009-12-29 | 2012-11-07 | 四川科伦药物研究有限公司 | Propyl gallate pre-emulsified concentrated solution and preparation thereof |
| CN101912362A (en) * | 2010-09-01 | 2010-12-15 | 北京大学 | A kind of fat emulsion pre-emulsified concentrate for intravenous injection of teniposide and preparation method thereof |
| CN111345290A (en) * | 2012-03-05 | 2020-06-30 | 阿彻丹尼尔斯米德兰德公司 | Microemulsions and their use as delivery systems |
| CN109414054A (en) * | 2016-07-19 | 2019-03-01 | 巴斯夫欧洲公司 | Vitamin prepared product containing propyl gallate |
| CN114010597A (en) * | 2021-11-25 | 2022-02-08 | 广州白云山汉方现代药业有限公司 | Propyl gallate fat emulsion injection with special grease proportion and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100333722C (en) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5981997B2 (en) | Sustained release lipid initial preparation of pharmacologically active substance and pharmaceutical composition containing the same | |
| CN1048182C (en) | Pharmaceutical carrier | |
| KR101267901B1 (en) | Emulsion composition comprising prostaglandin Ｅ1 | |
| CN1263447C (en) | Stable solution of reduced coenzyme Q | |
| CN1430503A (en) | O/W emulsion | |
| CN101032467A (en) | Superregulated long-cycled lipid emulsion carrying medicine reagent for mainline | |
| CN1261797A (en) | Self-emulsifying formulation forlipophilic compounds | |
| CN1688296A (en) | Injectable 2, 6-diisopropylphenol-containing anesthetic composition and methods | |
| CN105919949B (en) | A kind of flurbiprofen axetil freeze-drying breast of stabilization and preparation method thereof | |
| CN1857239A (en) | Coenzyme Q10 injection emulsion and its preparing process | |
| KR101443180B1 (en) | Novel Drug Delivery System for Percutaneous Absorption, Composition for External Preparation Preventing Hair Loss, and Cosmetics Using the Same | |
| JP2001522879A (en) | Composition containing azelaic acid | |
| TWI510243B (en) | Compositions and methods for the treatment of bladder cancer | |
| CN1682706A (en) | Stable oil-in-water emulsion of propyl gallate for vein and its preparing method | |
| CN1191832C (en) | Neovascularization promoters | |
| KR101735861B1 (en) | Pharmaceutical composition including a dha ester to be administered parenterally | |
| CN101057831A (en) | Docetaxel liposome novel preparations and its preparation method | |
| FI99080C (en) | Method for preparing emulsions for parenteral administration | |
| CN101716147A (en) | Alprostadil liposome microsphere preparation | |
| CN1298325C (en) | Stabilized oil-in-water emulsion of matrine alkaloid for venous purpose and production thereof | |
| CN101322688A (en) | Flumazenil oil-in-water emulsion for vein and preparation thereof | |
| CN1973826A (en) | Injection containing lipoid microsphere of etoposide and its prepn process | |
| CN1287773C (en) | Medicinal preparation containing brucea fruit oil | |
| CN1939315A (en) | Ganglioside solid lipid nano-particle of monosialic acid tetrahexose and its preparation | |
| CN107753428A (en) | Adapalene vesica and its preparation and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160304 Address after: 223001 No. 9 HANKOOK North Road, Jiangsu, Huaian Patentee after: Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070829 Termination date: 20180311 |